| Stereochemistry | ABSOLUTE |
| Molecular Formula | C13H16N2O |
| Molecular Weight | 216.2789 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C1C2=CC=CN=C2O[C@]13CN4CC[C@H]3CC4
InChI
InChIKey=OCKIPDMKGPYYJS-ZDUSSCGKSA-N
InChI=1S/C13H16N2O/c1-2-10-8-13(16-12(10)14-5-1)9-15-6-3-11(13)4-7-15/h1-2,5,11H,3-4,6-9H2/t13-/m0/s1
| Molecular Formula | C13H16N2O |
| Molecular Weight | 216.2789 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
AZD0328, a spirofuropyridine, is a selective alpha7 nicotinic receptor agonist. This drug participated in clinical trials phase II in patients with schizophrenia. However, studies were terminated because the drug didn’t meet the current target product profile. Besides AZD0328 has been studied in phase I for the treatment of Alzheimer's disease.
Originator
Approval Year
|
|
TARGET -> AGONIST |
Promising compounds acting as a α7 nAChR selective agonists seem to be also AZD0328 and TC-5619, both containing azabicyclooctane group. They are expected to be useful to treating multiple cognitive dysfunctions and schizophrenia .
|
Showing 1 to 1 of 1 entries